Pharmacokinetics of single dose sildenafil orally administered in canine models of chronic embolic pulmonary hypertension

Abstract

Information regarding the pharmacokinetics of oral sildenafil in dogs with pulmonary hypertension is limited. In this study, we examined the pharmacokinetics of oral sildenafil in a canine model of chronic embolic pulmonary hypertension (CEPH). The CEPH model was developed by repeatedly injecting microspheres into the pulmonary arteries. The pharmacokinetics of oral sildenafil at 1, 2 and 4 mg/kg was evaluated using four dogs with pulmonary hypertension in the fasted state. The plasma concentrations of sildenafil were determined using high-performance liquid chromatography, and pharmacokinetic parameters were calculated using a noncompartmental analysis. Sildenafil was well tolerated in this study. Proportional increments in the maximum plasma concentration and area under the curve extrapolated to infinity at drug doses of 1, 2 and 4 mg/kg were detected using a power model analysis. No significant differences were observed among the three doses in the time to maximum plasma concentration. The mean residence time and elimination half-life were slightly but significantly higher at a dose of 4 mg/kg than at a dose of 1 mg/kg.

Keywords: dog; microsphere; pharmacokinetics; pulmonary hypertension; sildenafil.

Fig. 1.

Plasma concentration profiles (mean and standard deviation) of sildenafil following oral administration at 1 (triangle), 2 (quadrangle) and 4 (circle) mg/kg in dogs with chronic embolic pulmonary hypertension (each n=4).